193 related articles for article (PubMed ID: 17465674)
1. Coping with viral diversity in HIV vaccine design.
Nickle DC; Rolland M; Jensen MA; Pond SL; Deng W; Seligman M; Heckerman D; Mullins JI; Jojic N
PLoS Comput Biol; 2007 Apr; 3(4):e75. PubMed ID: 17465674
[TBL] [Abstract][Full Text] [Related]
2. Coping with viral diversity in HIV vaccine design: a response to Nickle et al.
Fischer W; Liao HX; Haynes BF; Letvin NL; Korber B
PLoS Comput Biol; 2008 Jan; 4(1):e15; author reply e25. PubMed ID: 18225944
[No Abstract] [Full Text] [Related]
3. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
Rolland M; Jensen MA; Nickle DC; Yan J; Learn GH; Heath L; Weiner D; Mullins JI
J Virol; 2007 Aug; 81(16):8507-14. PubMed ID: 17537854
[TBL] [Abstract][Full Text] [Related]
4. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
5. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
6. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
7. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
8. Attenuated nef DNA vaccine construct induces cellular immune response: role in HIV-1 multiprotein vaccine.
Majumder B; Gray B; McBurney S; Schaefer TM; Dentchev T; Mahalingam S; Reinhart TA; Ayyavoo V
Immunol Lett; 2003 Oct; 89(2-3):207-14. PubMed ID: 14556980
[TBL] [Abstract][Full Text] [Related]
9. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
Fischer W; Perkins S; Theiler J; Bhattacharya T; Yusim K; Funkhouser R; Kuiken C; Haynes B; Letvin NL; Walker BD; Hahn BH; Korber BT
Nat Med; 2007 Jan; 13(1):100-6. PubMed ID: 17187074
[TBL] [Abstract][Full Text] [Related]
10. The rationale behind a vaccine based on multiple HIV antigens.
Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
12. Evolutionary and immunological implications of contemporary HIV-1 variation.
Korber B; Gaschen B; Yusim K; Thakallapally R; Kesmir C; Detours V
Br Med Bull; 2001; 58():19-42. PubMed ID: 11714622
[TBL] [Abstract][Full Text] [Related]
13. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
14. A long-term follow-up of an HIV type 1-infected patient reveals a coincidence of Nef-directed cytotoxic T lymphocyte effectors and high incidence of epitope-deleted variants.
Singh MK; Janvier G; Calvez V; Coulaud P; Rivière Y
AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1265-71. PubMed ID: 11559426
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
[TBL] [Abstract][Full Text] [Related]
16. Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice.
Liang X; Fu TM; Xie H; Emini EA; Shiver JW
Vaccine; 2002 Sep; 20(27-28):3413-21. PubMed ID: 12213412
[TBL] [Abstract][Full Text] [Related]
17. Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.
Patterson LJ; Malkevitch N; Zhao J; Peng B; Robert-Guroff M
DNA Cell Biol; 2002 Sep; 21(9):627-35. PubMed ID: 12396605
[TBL] [Abstract][Full Text] [Related]
18. Vaccines based on Nef and on Nef/DeltaV2 Env.
Erfle V; Goebel FD; Guzman CA; Le Grand R
Microbes Infect; 2005 Nov; 7(14):1400-4. PubMed ID: 16243564
[TBL] [Abstract][Full Text] [Related]
19. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
20. Criteria for selection of HIV vaccine candidates--general principles.
Ensoli B
Microbes Infect; 2005 Nov; 7(14):1433-5. PubMed ID: 16213181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
